Agata Pietrzycka

Agata Pietrzycka

Auto-generated profile, based on publicly available information

Agata Pietrzycka

Department of Pharmacobiology, Jagiellonian University Medical College, Krakow, Poland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Journal of Chromatography A
Verified
Journal Article
Closed access
BGBeata Grabowska-Polanowska
Beata Grabowska-Polanowska
JFJacek Faber
Jacek Faber
MSMonika Skowron
Monika Skowron
PMPrzemysław Miarka
Przemysław Miarka
APAgata Pietrzycka
Agata Pietrzycka
AAAnton Amann
Anton Amann

1 January 2007 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
MKMaria Kapiszewska
Maria Kapiszewska
ACAgnieszka Cierniak
Agnieszka Cierniak
MPMonika Papież
Monika Papież
APAgata Pietrzycka
Agata Pietrzycka
MSMarek Stepniewski
Marek Stepniewski
ALAdam Lomnicki
Adam Lomnicki
The DNA damage in bone marrow cells induced by etoposide (E) injected intraperitoneally to rats (100 mg/kg b.w.) decreased to the control level when quercetin (Q) was administered subcutaneously for 10 consecutive days (40 mg/kg b.w.per day) before E was injected. The antioxidant power (FRAP assay) increased significantly after Q or E compared with control rats but did not change when Q preceded the E injection. The superoxide dismutase activity significantly increased in Q+E-treated rats compared with quercetin given alone. The study provides evidence that Q protects bone marrow cells against long-lived E-induced DNA damage and alters the redox balance in lung tissue.

1 August 2017 in Journal of Chromatography B
Verified
Journal Article
Closed access
BGBeata Grabowska-Polanowska
Beata Grabowska-Polanowska
MSM. Skowron
M. Skowron
PMP. Miarka
P. Miarka
APA. Pietrzycka
A. Pietrzycka
IŚI. Śliwka
I. Śliwka

3 June 2015 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
KKKatarzyna Krzanowska
Katarzyna Krzanowska
MKMarcin Krzanowski
Marcin Krzanowski
MGMariusz Gajda
Mariusz Gajda
Paulina DumnickaPaulina Dumnicka
Paulina Dumnicka
DFDanuta Fedak
Danuta Fedak
WSWładysław Sułowicz
Władysław Sułowicz
The objective of the study was to determine the relationship between common carotid artery intima-media thickness (CCA-IMT) and histologically assessed calcification of radial artery in relation to clinical features and laboratory markers of bone and mineral metabolism, inflammation, and oxidative stress in patients with stage 5 chronic kidney disease (CKD). The study comprised 59 patients (36 hemodialyzed, 23 predialysis). CCA-IMT was measured by ultrasonography; the biochemical parameters examined were assessed using routine laboratory methods, ELISA micro-plate immunoassays and spectrophotometry. Fragments of radial artery obtained during creation of hemodialysis access were cryosectioned and stained for calcifications using von Kossa method and alizarin red. Glucose, osteoprotegerin, pentraxin 3 and Framingham risk score significantly correlated with CCA-IMT. In multiple regression analysis, OPG positively predicted CCA-IMT. Radial artery calcifications were found in 34 patients who showed higher CCA-IMT (0.98 ± 0.13 vs 0.86 ± 0.14 mm; P = 0.006). Higher CCA-IMT values were also associated with more advanced calcifications. CCA-IMT and the presence of plaques in common carotid artery were positive predictors of radial artery calcifications, independent of dialysis status, Framingham risk score, CRP and Ca x Pi [OR for calcifications 2.19 (1.08-4.45) per 0.1 mm increase in CCA-IMT]. The presence of radial artery calcifications was a significant predictor of mortality, independent of dialysis status and Framingham risk score [HR 3.16 (1.03-9.64)]. In CKD patients, CCA-IMT examination can be used as a surrogate measure to assess the incidence and severity of arterial medial calcification which is associated with poor clinical outcome in these patients.

1 January 2015 in Disease Markers
Verified
Journal Article
Open access
PDF file
KKKatarzyna Krzanowska
Katarzyna Krzanowska
MKMarcin Krzanowski
Marcin Krzanowski
MGMariusz Gajda
Mariusz Gajda
Paulina DumnickaPaulina Dumnicka
Paulina Dumnicka
EJEwa Jasek-Gajda
Ewa Jasek-Gajda
WSWładysław Sułowicz
Władysław Sułowicz
Objectives.Our aim was to determine whether vascular deposition of advanced glycation end-products (AGEs) is associated with arterial calcification and cardiovascular mortality in chronic kidney disease (CKD) patients and to assess the relationships between vascular content of AGEs and selected clinical and biochemical parameters.Materials and Methods.The study comprised 54 CKD patients (33 hemodialyzed, 21 predialyzed). Examined parameters included BMI, incidence of diabetes, plasma fasting glucose, AGEs, soluble receptor for AGEs and 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging, serum C-reactive protein (hsCRP), plasminogen activator inhibitor-1 (PAI-1), and fetuin-A. Fragments of radial artery obtained during creation of hemodialysis access were stained for calcifications using alizarin red. AGEs deposits were identified immunohistochemically and their relative content was quantified.Results.Vascular content of AGEs was positively correlated with BMI, hsCRP, fetuin-A, PAI-1, and DPPH scavenging in simple regression; only fetuin-A was an independent predictor in multiple regression. There was a significant positive trend in the intensity of AGEs immunostaining among patients with grades 1, 2, and 3 calcifications. AGEs immunostaining intensity predicted 3-year cardiovascular mortality irrespective of patient’s age.Conclusions.The present study demonstrates an involvement of AGEs in the development of medial arterial calcification and the impact of arterial AGE deposition on cardiovascular mortality in CKD patients.

9 October 2015 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
APAgata Pietrzycka
Agata Pietrzycka
MKMariusz Kózka
Mariusz Kózka
TUTomasz Urbanek
Tomasz Urbanek
MSMarek St.PNiewski
Marek St.PNiewski
MKMarek Kucharzewski
Marek Kucharzewski
Objective The aetiology of varicose veins involves various factors and pathomechanisms including endothelial cell activation or dysfunction, venous hypertension, vein wall hypoxia, shear stress disturbances, inflammatory reaction activation or free radical production. To improve our understanding of the mechanisms of potential pharmacological interventions for chronic venous disease, we evaluated the influence of micronized purified flavonoid fraction (MPFF) on the relationship between antioxidant enzyme balance, endothelin-1 (ET-1) and tumour necrosis factor-α (TNF-α) levels. Material and Methods Blood samples were obtained from 89 women with primary varicose veins; 34 were treated with MPFF and 55 did not receive any phlebotropic drug treatment. For the evaluation of the blood antioxidant enzyme balance, catalase (CAT) and superoxide dismutase (SOD) activity was assessed and the CAT/SOD ratio was calculated. Results Patients taking MPFF had significantly lower ET-1 levels than those not taking MPFF [median (25-75th quartile): 24.2 (22.30-27.87) vs 37.62 (24.9-44.58) pg.ml-1; p <0.05]. In those taking MPFF, a higher CAT/SOD ratio [39.8 (24.7-72.6) vs 28.8 (16.3-57.7); p<0.05] and a lower TNF-α concentration [6.82 (4.42-13.39) vs 12.94 (6.01-27.33) pg.ml-1; p<0.05] was also observed. In women not taking MPFF, ET-1 levels increased with the CAT/SOD ratio. In those taking MPFF, the ET-1 level was stable at approximately 25.0 pg.ml-1¬ up to a CAT/SOD ratio of 100. TNF-α level increased continuously with an increasing CAT/SOD ratio; however, the highest levels of TNF-α were observed in women not taking MPFF. Conclusion We demonstrate the ability of MPFF to effectively lower the levels of ET-1 and TNF-α in patients with chronic venous disease. Further investigations are needed to define the therapeutic potential of MPFF including the potential effect on chronic subclinical inflammation, antioxidant imbalance and vascular dysfunction during the development of chronic venous disease.